本栏目刊登的ICH指导原则中文翻译非CFDA官方发布的正式稿件,仅供参考。
编号 | 阶段 | 发布日期 | 内容 |
M1 MedDRA Terminology (监管活动医学术语) | |||
M1 | Version 20.1 | 2017-9 | Medical Dictionary for Regulatory Activities(MedDRA ) |
监管活动医学术语 | |||
M2 Electronic Standards (电子标准) | |||
M2 | Electronic Standards for the Transfer of Regulatory Information(ESTRI) | ||
监管信息传输电子标准 | |||
M3 Nonclinical Safety Studies (非临床安全性研究) | |||
M3(R2) | Step 5 | 2009-6-11 | Guidance on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals |
药物进行人体临床试验和上市许可申请的非临床安全性研究指导原则 | |||
M3(R2) Q&As (R2) | Step 5 | 2012-3-5 | Questions & Answers: Guidance on Non-Clinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals |
M3的问与答 | |||
M4 Common Technical Document (通用技术文件) | |||
M4 | The Common Technical Document(CTD) | ||
通用技术文件 | |||
M4(R4) | Step 5 | 2016-6-15 | Organisation of the Common Technical Document For The Registration of Pharmaceuticals for human use |
人用药物注册申请的通用技术文件组织结构 | |||
M4Q(R1) | Step 5 | 2002-9-12 | The Common Technical Document for the Registation of Pharmaceuticals for Human Use: Quality |
人用药物注册申请的通用技术文件:质量 | |||
M4S(R2) | Step 5 | 2002-12-20 | The Common Technical Document for the Registration of Pharmaceuticals for human Use: Safety |
人用药物注册申请的通用技术文件:安全性 | |||
M4E(R1) | Step 5 | 2002-9-12 | The Common Technical Document for the Registration of Pharmaceuticals for Human Use:Efficacy |
人用药物注册申请的通用技术文件:有效性 | |||
M4E(R2) | Step 5 | 2016-6-15 | Revision of M4e Guideline on Enhancing the Format and Structure of Benefit-risk Information in Ich |
M4E指南修订,优化临床研究风险评估的格式与结构 | |||
M5 Data Elements and Standards for Drug Dictionaries (药物词汇的数据要素和标准) | |||
M5 | Data Elements and Standards for Drug Dictionaries | ||
药物词汇的数据要素和标准 | |||
M6 Gene Therapy (基因治疗) | |||
M6 | Virus and Gene Therapy Vector Shedding and Transmission | ||
病毒和基因治疗载体的脱落和传播 | |||
M7 Genotoxic Impurities (基因毒性杂质) | |||
M7(R1) | Step 5 | 2017-3-31 | Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk |
为限制潜在致癌风险而对药物中DNA活性(诱变性)杂质进行的评估和控制 | |||
M8 Electronic Common Technical Document (eCTD) (电子通用技术文件) | |||
M8 | Step 4 | Electronic Common Technical Document (eCTD) | |
电子通用技术文件 | |||
M9 Biopharmaceutics Classification System-based Biowaivers (基于生物药剂学分类系统的生物豁免) | |||
M9 | Step 1 | Biopharmaceutics Classification System-based Biowaivers | |
基于生物药剂学分类系统的生物豁免 | |||
M10 Bioanalytical Method Validation (生物样品分析的方法验证) | |||
M10 | Step 1 | Bioanalytical Method Validation | |
生物样品分析的方法验证 |
版权所有 国家药品监督管理局食品药品审核查验中心 未经许可禁止转载或建立镜像
京公网安备 11010202007695号 京 ICP 备 09098178 号
地址:北京市大兴区旧宫镇广德大街22号院中科电商谷C区一区5号楼 邮编 100076 联系电话:68441000 传真:68441300
总访问量:1353450 昨日访问量:6494 今日访问量:11333
【微信公众号】